<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Patients with lung cancer have an increased vulnerability to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection, and the association of the two diseases increases the severity of the infection. We present the case of a patient aged 72 years, a former 30 pack year (PA) smoker with 12 years withdrawal, and unvaccinated anti-SARS-CoV-2, with GOLD 2 COPD, hypertensive, recently diagnosed with left bronchopulmonary neoplasm and under immunotherapy. The patient had a fast-evolving SARS-COVID infection to a critical form, complicated with acute pulmonary embolism, nosocomial fungal infection, myelodysplastic syndrome, moderate multifactorial anaemic syndrome and heart disease. The unfavourable evolution of the patient’s condition led to the temporary suspension of oncological treatment throughout the critical period, but without the progression of neoplastic disease. Although bronchopulmonary neoplasm emphasises the severity of SARS-CoV-2 infection, it is not mandatory to develop a harmful oncologic outcome without proper treatment, especially immunotherapy.</p>
</abstract>

Patients with lung cancer have an increased vulnerability to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection, and the association of the two diseases increases the severity of the infection. We present the case of a patient aged 72 years, a former 30 pack year (PA) smoker with 12 years withdrawal, and unvaccinated anti-SARS-CoV-2, with GOLD 2 COPD, hypertensive, recently diagnosed with left bronchopulmonary neoplasm and under immunotherapy. The patient had a fast-evolving SARS-COVID infection to a critical form, complicated with acute pulmonary embolism, nosocomial fungal infection, myelodysplastic syndrome, moderate multifactorial anaemic syndrome and heart disease. The unfavourable evolution of the patient’s condition led to the temporary suspension of oncological treatment throughout the critical period, but without the progression of neoplastic disease. Although bronchopulmonary neoplasm emphasises the severity of SARS-CoV-2 infection, it is not mandatory to develop a harmful oncologic outcome without proper treatment, especially immunotherapy.

Impact of SARS-CoV-2 on lung cancer patient under immunotherapy

Universitatea de Medicină și Farmacie “Carol Davila”

Pneumologia

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Impact of SARS-CoV-2 on lung cancer patient under immunotherapy"}

Patients with lung cancer have an increased vulnerability to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection, and the association...

Impact of SARS-CoV-2 on lung cancer patient under immunotherapy

Data publikacji: 17 paź 2023

Zakres stron: 89 - 97

DOI: https://doi.org/10.2478/pneum-2023-0027

Słowa kluczowe
bronchopulmonary cancer, COVID-19, SARS-CoV-2

© 2022 Rinedy Mondonga Lisumbu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Impact of SARS-CoV-2 on lung cancer patient under immunotherapy

Data publikacji: 17 paź 2023

Zakres stron: 89 - 97

DOI: https://doi.org/10.2478/pneum-2023-0027

Słowa kluczowebronchopulmonary cancer, COVID-19, SARS-CoV-2

© 2022 Rinedy Mondonga Lisumbu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Słowa kluczowe
bronchopulmonary cancer, COVID-19, SARS-CoV-2